About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Crohn
Crohn's Disease Therapeutics Market

Crohn's Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (TNF-Alpha inhibitors, 5-Aminosalicylates, Others), By Gender Type (Men, Women), By Disease Type (Small/Large Intestinal Type, Large Intestinal Type, Small Intestinal Type), By Age Group (49 yrs. and below, 50 yrs. and above) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI3518DR
Last Updated : February 19, 2024
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Crohn's Disease Therapeutics Market Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. TNF-Alpha inhibitors
        1. By Value
      3. 5-Aminosalicylates
        1. By Value
      4. Others
        1. By Value
    3. By Gender Type
      1. Introduction
        1. Gender Type By Value
      2. Men
        1. By Value
      3. Women
        1. By Value
    4. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Small/Large Intestinal Type
        1. By Value
      3. Large Intestinal Type
        1. By Value
      4. Small Intestinal Type
        1. By Value
    5. By Age Group
      1. Introduction
        1. Age Group By Value
      2. 49 yrs. and below
        1. By Value
      3. 50 yrs. and above
        1. By Value
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. TNF-Alpha inhibitors
        1. By Value
      3. 5-Aminosalicylates
        1. By Value
      4. Others
        1. By Value
    3. By Gender Type
      1. Introduction
        1. Gender Type By Value
      2. Men
        1. By Value
      3. Women
        1. By Value
    4. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Small/Large Intestinal Type
        1. By Value
      3. Large Intestinal Type
        1. By Value
      4. Small Intestinal Type
        1. By Value
    5. By Age Group
      1. Introduction
        1. Age Group By Value
      2. 49 yrs. and below
        1. By Value
      3. 50 yrs. and above
        1. By Value
    6. U.S.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. TNF-Alpha inhibitors
          1. By Value
        3. 5-Aminosalicylates
          1. By Value
        4. Others
          1. By Value
      2. By Gender Type
        1. Introduction
          1. Gender Type By Value
        2. Men
          1. By Value
        3. Women
          1. By Value
      3. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Small/Large Intestinal Type
          1. By Value
        3. Large Intestinal Type
          1. By Value
        4. Small Intestinal Type
          1. By Value
      4. By Age Group
        1. Introduction
          1. Age Group By Value
        2. 49 yrs. and below
          1. By Value
        3. 50 yrs. and above
          1. By Value
    7. Canada
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. TNF-Alpha inhibitors
        1. By Value
      3. 5-Aminosalicylates
        1. By Value
      4. Others
        1. By Value
    3. By Gender Type
      1. Introduction
        1. Gender Type By Value
      2. Men
        1. By Value
      3. Women
        1. By Value
    4. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Small/Large Intestinal Type
        1. By Value
      3. Large Intestinal Type
        1. By Value
      4. Small Intestinal Type
        1. By Value
    5. By Age Group
      1. Introduction
        1. Age Group By Value
      2. 49 yrs. and below
        1. By Value
      3. 50 yrs. and above
        1. By Value
    6. U.K.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. TNF-Alpha inhibitors
          1. By Value
        3. 5-Aminosalicylates
          1. By Value
        4. Others
          1. By Value
      2. By Gender Type
        1. Introduction
          1. Gender Type By Value
        2. Men
          1. By Value
        3. Women
          1. By Value
      3. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Small/Large Intestinal Type
          1. By Value
        3. Large Intestinal Type
          1. By Value
        4. Small Intestinal Type
          1. By Value
      4. By Age Group
        1. Introduction
          1. Age Group By Value
        2. 49 yrs. and below
          1. By Value
        3. 50 yrs. and above
          1. By Value
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest of Europe
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. TNF-Alpha inhibitors
        1. By Value
      3. 5-Aminosalicylates
        1. By Value
      4. Others
        1. By Value
    3. By Gender Type
      1. Introduction
        1. Gender Type By Value
      2. Men
        1. By Value
      3. Women
        1. By Value
    4. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Small/Large Intestinal Type
        1. By Value
      3. Large Intestinal Type
        1. By Value
      4. Small Intestinal Type
        1. By Value
    5. By Age Group
      1. Introduction
        1. Age Group By Value
      2. 49 yrs. and below
        1. By Value
      3. 50 yrs. and above
        1. By Value
    6. China
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. TNF-Alpha inhibitors
          1. By Value
        3. 5-Aminosalicylates
          1. By Value
        4. Others
          1. By Value
      2. By Gender Type
        1. Introduction
          1. Gender Type By Value
        2. Men
          1. By Value
        3. Women
          1. By Value
      3. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Small/Large Intestinal Type
          1. By Value
        3. Large Intestinal Type
          1. By Value
        4. Small Intestinal Type
          1. By Value
      4. By Age Group
        1. Introduction
          1. Age Group By Value
        2. 49 yrs. and below
          1. By Value
        3. 50 yrs. and above
          1. By Value
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Singapore
    12. Taiwan
    13. South East Asia
    14. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. TNF-Alpha inhibitors
        1. By Value
      3. 5-Aminosalicylates
        1. By Value
      4. Others
        1. By Value
    3. By Gender Type
      1. Introduction
        1. Gender Type By Value
      2. Men
        1. By Value
      3. Women
        1. By Value
    4. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Small/Large Intestinal Type
        1. By Value
      3. Large Intestinal Type
        1. By Value
      4. Small Intestinal Type
        1. By Value
    5. By Age Group
      1. Introduction
        1. Age Group By Value
      2. 49 yrs. and below
        1. By Value
      3. 50 yrs. and above
        1. By Value
    6. UAE
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. TNF-Alpha inhibitors
          1. By Value
        3. 5-Aminosalicylates
          1. By Value
        4. Others
          1. By Value
      2. By Gender Type
        1. Introduction
          1. Gender Type By Value
        2. Men
          1. By Value
        3. Women
          1. By Value
      3. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Small/Large Intestinal Type
          1. By Value
        3. Large Intestinal Type
          1. By Value
        4. Small Intestinal Type
          1. By Value
      4. By Age Group
        1. Introduction
          1. Age Group By Value
        2. 49 yrs. and below
          1. By Value
        3. 50 yrs. and above
          1. By Value
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest of MEA
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. TNF-Alpha inhibitors
        1. By Value
      3. 5-Aminosalicylates
        1. By Value
      4. Others
        1. By Value
    3. By Gender Type
      1. Introduction
        1. Gender Type By Value
      2. Men
        1. By Value
      3. Women
        1. By Value
    4. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Small/Large Intestinal Type
        1. By Value
      3. Large Intestinal Type
        1. By Value
      4. Small Intestinal Type
        1. By Value
    5. By Age Group
      1. Introduction
        1. Age Group By Value
      2. 49 yrs. and below
        1. By Value
      3. 50 yrs. and above
        1. By Value
    6. Brazil
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. TNF-Alpha inhibitors
          1. By Value
        3. 5-Aminosalicylates
          1. By Value
        4. Others
          1. By Value
      2. By Gender Type
        1. Introduction
          1. Gender Type By Value
        2. Men
          1. By Value
        3. Women
          1. By Value
      3. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Small/Large Intestinal Type
          1. By Value
        3. Large Intestinal Type
          1. By Value
        4. Small Intestinal Type
          1. By Value
      4. By Age Group
        1. Introduction
          1. Age Group By Value
        2. 49 yrs. and below
          1. By Value
        3. 50 yrs. and above
          1. By Value
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest of LATAM
    1. Crohn's Disease Therapeutics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. AbbVieInc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Biogen
    3. Takeda
    4. Janssen BiotechInc. (Johnson & Johnson)
    5. Bristol-Myers Squibb
    6. AstraZeneca
    7. Pfizer
    8. Red Hill Pharma
    9. 4D Pharma
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global microbiome therapeutics market size was worth USD 380 million in 2022 and is estimated to reach an expected value of USD 2,400 million by 2031, growing at a CAGR of 24.8% during the forecast period (2023 – 2031). Microbiome therapeu
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright . All rights Reserved.